| Similar Articles |
|---|
 |
The Motley Fool
April 25, 2005
Charly Travers |
Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around?   |
The Motley Fool
January 21, 2005
Charly Travers |
Seeing the Value in QLT A narrow-minded market could be creating a great drug value. |
The Motley Fool
August 31, 2004
Charly Travers |
Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one. |
The Motley Fool
June 15, 2004
Charly Travers |
QLT Swallows Atrix Atrix Laboratories has been purchased by Canadian drug company QLT. For Atrix shareholders, the timing of this deal must be incredibly frustrating. |
The Motley Fool
July 5, 2006
Brian Lawler |
Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid. |
The Motley Fool
March 29, 2005
Charly Travers |
A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT. |
The Motley Fool
February 26, 2007
Brian Lawler |
Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007. |
The Motley Fool
August 31, 2007
Brian Lawler |
QLT Gets Reformulated Drug developer QLT announced that an EU approval will open new markets for the cancer drug that could edge out the competition by lowering overall medical costs. |
The Motley Fool
April 28, 2005
Charly Travers |
QLT's a Clutch Performer Pharma continues to deliver growth through difficult times. |
The Motley Fool
September 12, 2006
Brian Lawler |
Those Buybacks at QLT Is the biopharmaceutical repurchasing shares to make itself more attractive for an acquisition? Investors, take note. |
The Motley Fool
October 29, 2007
Brian Lawler |
QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs. |
The Motley Fool
November 29, 2007
Brian Lawler |
QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale. |
The Motley Fool
January 22, 2007
Brian Lawler |
QLT's Sagging Sales The drug developer's macular degeneration treatment has seen declining sales. And as sales fall, so too does the percent of profits that QLT keeps. Investors, take note. |
The Motley Fool
October 26, 2006
Brian Lawler |
QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note. |
The Motley Fool
April 24, 2007
Brian Lawler |
Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound. |
The Motley Fool
March 20, 2008
Brian Orelli |
Abbott and Takeda's Partnership TAPed Out It looks like Abbott Laboratories and Takeda will be ending their 30-year joint partnership with a 50/50 split. |
The Motley Fool
July 17, 2007
Brian Lawler |
QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate. |
The Motley Fool
June 8, 2007
Brian Lawler |
QLT Eats Itself The beleaguered specialty pharmaceutical opens up another share buyback plan. |
The Motley Fool
June 10, 2008
Brian Lawler |
Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies. |
The Motley Fool
March 18, 2008
Brian Lawler |
QLT's Blemished Aczone Clears Up A more lenient label from the FDA is good news for this drugmaker. |
The Motley Fool
April 1, 2004
Charly Travers |
Atrix Batting 1.000 Atrix Laboratories' drugs have breezed past the Food and Drug Administration. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
BusinessWeek
October 18, 2004
Gene G. Marcial |
Is Pfizer Eyeing Eyetech? Pfizer may buy Eyetech after its Macugen ophthalmology product is approved. And a Merrill Lynch analyst calls Eyetech stock "a buy," saying it should turn profitable in 2005, earning 19 cents a share, and 81 cents in 2006. |
The Motley Fool
August 22, 2005
Rich Duprey |
Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies. |
The Motley Fool
May 24, 2005
Charly Travers |
Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note. |
The Motley Fool
January 18, 2005
Charly Travers |
Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
The Motley Fool
May 31, 2005
Karl Thiel |
Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels. |
